These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL; Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262 [TBL] [Abstract][Full Text] [Related]
23. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Swisher EM; Aghajanian C; O'Malley DM; Fleming GF; Kaufmann SH; Levine DA; Birrer MJ; Moore KN; Spirtos NM; Shahin MS; Reid TJ; Friedlander M; Steffensen KD; Okamoto A; Sehgal V; Ansell PJ; Dinh MH; Bookman MA; Coleman RL Gynecol Oncol; 2022 Feb; 164(2):245-253. PubMed ID: 34906376 [TBL] [Abstract][Full Text] [Related]
24. Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors. Lord R; Rauniyar J; Morris T; Condon O; Jones R; Miller R; Hall M; Lofts F; Glasspool RM; Hudson E Int J Gynecol Cancer; 2020 Jul; 30(7):1026-1033. PubMed ID: 32321768 [TBL] [Abstract][Full Text] [Related]
25. Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with Zhou S; Jiang Y; Luo C; Yuan L Expert Rev Anticancer Ther; 2024; 24(1-2):59-69. PubMed ID: 38174379 [TBL] [Abstract][Full Text] [Related]
26. Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis. Fazekas T; Széles ÁD; Teutsch B; Csizmarik A; Vékony B; Kói T; Ács N; Hegyi P; Hadaschik B; Nyirády P; Szarvas T Eur Urol Oncol; 2024 Jun; 7(3):365-375. PubMed ID: 37722977 [TBL] [Abstract][Full Text] [Related]
27. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression. Lheureux S; Oaknin A; Garg S; Bruce JP; Madariaga A; Dhani NC; Bowering V; White J; Accardi S; Tan Q; Braunstein M; Karakasis K; Cirlan I; Pedersen S; Li T; Fariñas-Madrid L; Lee YC; Liu ZA; Pugh TJ; Oza AM Clin Cancer Res; 2020 Aug; 26(16):4206-4215. PubMed ID: 32444417 [TBL] [Abstract][Full Text] [Related]
28. PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials. Baradács I; Teutsch B; Váradi A; Bilá A; Vincze Á; Hegyi P; Fazekas T; Komoróczy B; Nyirády P; Ács N; Bánhidy F; Lintner B J Ovarian Res; 2024 Feb; 17(1):53. PubMed ID: 38409030 [TBL] [Abstract][Full Text] [Related]
29. PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients. Gauduchon T; Kfoury M; Lorusso D; Floquet A; Ventriglia J; Salaun H; Moubarak M; Rivoirard R; Polastro L; Favier L; You B; Berton D; de la Motte Rouge T; Mansi L; Abdeddaim C; Prulhiere K; Lancry Lecomte L; Provansal M; Dalban C; Ray-Coquard I Gynecol Oncol; 2023 Jun; 173():98-105. PubMed ID: 37105063 [TBL] [Abstract][Full Text] [Related]
30. [The efficacy and safety of anlotinib combined with niraparib in treating patients with platinum-resistant recurrent ovarian cancer]. Yang M; Wang JJ; Deng SQ; Liang SS; Sun L Zhonghua Zhong Liu Za Zhi; 2024 Jul; 46(7):696-702. PubMed ID: 39034805 [No Abstract] [Full Text] [Related]
31. Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance. Levine MD; Wang H; Sriram B; Khan A; Senter L; McLaughlin EM; Bixel KL; Chambers LM; Cohn DE; Copeland LJ; Cosgrove CM; Nagel CI; O'Malley DM; Backes FJ Gynecol Oncol; 2024 Mar; 182():51-56. PubMed ID: 38262238 [TBL] [Abstract][Full Text] [Related]
32. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458 [No Abstract] [Full Text] [Related]
33. Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. DiSilvestro P; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian CA; Bradley WH; Mathews CA; Liu J; Lowe ES; Bloomfield R; Moore KN J Clin Oncol; 2020 Oct; 38(30):3528-3537. PubMed ID: 32749942 [TBL] [Abstract][Full Text] [Related]
35. Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis. Suh YJ; Lee B; Kim K; Jeong Y; Choi HY; Hwang SO; Kim YB BMC Cancer; 2022 Mar; 22(1):346. PubMed ID: 35354431 [TBL] [Abstract][Full Text] [Related]
36. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. Bartoletti M; Pelizzari G; Gerratana L; Bortot L; Lombardi D; Nicoloso M; Scalone S; Giorda G; Baldassarre G; Sorio R; Puglisi F Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471250 [TBL] [Abstract][Full Text] [Related]
37. Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. Tjokrowidjaja A; Friedlander M; Lord SJ; Asher R; Rodrigues M; Ledermann JA; Matulonis UA; Oza AM; Bruchim I; Huzarski T; Gourley C; Harter P; Vergote I; Scott CL; Meier W; Shapira-Frommer R; Milenkova T; Pujade-Lauraine E; Gebski V; Lee CK Eur J Cancer; 2021 Sep; 154():190-200. PubMed ID: 34293664 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: a cross-sectional study. Cerda VR; Lu D; Scott M; Kim KH; Rimel BJ; Kamrava M Int J Gynecol Cancer; 2022 Feb; 32(2):153-158. PubMed ID: 34911701 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]